Literature DB >> 6259059

A possible antihypertensive mechanism of propranolol: antagonism of angiotensin II enhancement of sympathetic nerve transmission through prostaglandins.

E K Jackson, W B Campbell.   

Abstract

The effects of propranolol on angiotensin II (AII) enhancement of sympathetic nerve transmission were investigated in the in situ blood-perfused mesenteric vascular bed of the rat. Angiotensin II in subpressor concentrations (3 ng/ml) potentiated the vasoconstrictor responses to both sympathetic nerve stimulation (NS) and exogenous norepinephrine (NE). The dl-propranolol had no effect on the basal vasoconstrictor responses to NS and NE, yet inhibited the AII-enhanced vasoconstrictor responses to NS by 47% (p less than 0.05) and 81% (p less than 0.001) at 100 and 300 ng/ml respectively. In contrast, the potentiation of NE responses by AII was unaffected by propranolol. A similar blockade of AII enhancement of NS was observed with the d-isomer of propranolol. Dibucaine (300 ng/ml), a local anesthetic, failed to alter the basal or AII-enhanced responses to either NS or NE. Indomethacin, a prostaglandin synthetase inhibitor (5 mg/kg, s.c.), abolished the inhibitory effect of dl-propranolol on AII enhancement of NS. Prostaglandin E2 (PGE2), but not prostaglandin I2, (3 ng/ml) inhibited AII enhancement of NS without altering the basal response to NS or NE in indomethacin-pretreated animals. Intraarterial infusions of dl-propranolol, d-propranolol, AII, and dl-propranolol-plus-AII into the superior mesenteric artery increased mesenteric venous PGE2 concentrations from 216 +/- 33 to 355 +/- 33 (p less than 0.01), 328 +/- 44 (p less than 0.05), 325 +/- 27 (p less than 0.02), and 407 +/- 44 pg/ml (p less than 0.01) respectively. We conclude that propranolol antagonizes AII enhancement of NS by increasing prostaglandin levels in vascular tissue. Furthermore, these findings suggest that propranolol may exert its antihypertensive effect through the release of prostaglandins when used in therapeutic doses in excess of those required for beta-adrenergic blockade.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6259059     DOI: 10.1161/01.hyp.3.1.23

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Propranolol and atenolol inhibit norepinephrine spillover rate into plasma in conscious spontaneously hypertensive rats.

Authors:  T K Keeton; A M Biediger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

2.  Exercise-induced increments in plasma levels of propranolol and noradrenaline.

Authors:  G A Hurwitz; J G Webb; T Walle; S A Bai; H B Daniell; L Gourley; C Boyd Loadholt; T E Gaffney
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

3.  Alkaline Phosphatase Inhibitors Attenuate Renovascular Responses to Norepinephrine.

Authors:  Edwin K Jackson; Yumeng Zhang; Dongmei Cheng
Journal:  Hypertension       Date:  2017-01-30       Impact factor: 10.190

4.  Inhibition of vasoconstriction by frusemide in the rat.

Authors:  J F Gerkens; A J Smith
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

5.  Angiotensin III-induced modulation of neurogenic responses in the rabbit vas deferens and portal vein.

Authors:  G J Trachte; E J Sybertz; M Michener; S B Binder; M J Peach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-07       Impact factor: 3.000

6.  An electrophysiological study of the actions of angiotensin II at the sympathetic neuroeffector junction in the guinea-pig vas deferens.

Authors:  J Ziogas; T C Cunnane
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

7.  Effects of thromboxane synthase inhibition on vascular responsiveness in the in vivo rat mesentery.

Authors:  E K Jackson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

8.  Addition of Propranolol in Resistant Arterial hypertension Treatment (APROPRIATE study): study protocol for a randomized double-blind placebo-controlled trial.

Authors:  G R Constantine; P Ranasinghe; P Weeratunga; C Weeraratne; P Galappatthy; S Rajapakse; U Senarath; P Katulanda
Journal:  Trials       Date:  2017-03-14       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.